FDA approves Siemens subsidiary's PET tracer
This article was originally published in Clinica
PETNet Solutions, a subsidiary of imaging giant Siemens Healthcare, has received US approval for its PET tracer, Fludeoxyglucose (FDG) 18F Injection. Siemens Healthcare's Mark Palacio told Clinica that PETNet (Knoxville, Tennessee) is the first company to achieve approval of an abbreviated new drug application (ANDA) for FDG. 18F FDG is used to assess cancer patients for abnormal glucose metabolism, to assist in the evaluation of known or suspected abnormalities. It is also used in cardiology and neurology. The firm expects to see "significant benefits" in patient safety owing to "the tightly controlled manufacturing processes that are commensurate with an FDA-approved pharmaceutical". In fiscal year 2010, Siemens Healthcare posted revenue of €12.4bn and profit of around €750m.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.